The results varied significantly in severity
To view a copy of this licence, visit About this article Cite this article Dubsk, M., Sojkov, D., Fejfarov, V
Summary: Retatrutide is not yet approved by the MHRA or EMA and cannot be considered definitively safe, as it remains an investigational drug with an incompletely characterised safety profile based only on Phase 2 trial data
Feeling fuller faster simply allows us to stop eating when we've had enough, instead of being driven by compulsion or boredom
The extra peptide isnt about more is better for its own sake its about matching the tool to a genuinely more complex problem
While rare instances of adverse reproductive effects have been noted, current data do not indicate any widespread detrimental impact on male fertility